Literature DB >> 27492806

Incidental Dose to Pelvic Nodal Regions in Prostate-Only Radiotherapy.

Vedang Murthy1, Shirley Lewis1, Mayur Sawant2, Siji N Paul2, Umesh Mahantshetty1, Shyam Kishore Shrivastava1.   

Abstract

OBJECTIVES: Pelvic lymph nodal regions receive an incidental dose from conformal treatment of the prostate. This study was conducted to investigate the doses received by the different pelvic nodal regions with varying techniques used for prostate radiotherapy. METHODS AND MATERIALS: Twenty patients of high-risk node-negative prostate cancer treated with intensity-modulated radiotherapy to the prostate alone were studied. Replanning was done for intensity-modulated radiotherapy, 3-dimensional conformal treatment, and 2-dimensional conventional radiotherapy with additional delineation of the pelvic nodal regions, namely, common iliac (upper and lower), presacral, internal iliac, obturator, and external iliac. Dose-volume parameters such as Dmean, D100%, D66%, D33%, V40, and V50 to each of the nodal regions were estimated for all patients.
RESULTS: The obturator nodes received the highest dose among all nodal regions. The mean dose received by obturator nodal region was 44, 29, and 22 Gy from 2-dimensional conventional radiotherapy, 3-dimensional conformal treatment, and intensity-modulated radiotherapy, respectively. The mean dose was significantly higher when compared between 2-dimensional conventional radiotherapy and 3-dimensional conformal treatment ( P < .001), 2-dimensional conventional radiotherapy and intensity-modulated radiotherapy ( P < .001), and 3-dimensional conformal treatment and intensity-modulated radiotherapy ( P < .001). The D33% of the obturator region was 64, 39, and 37 Gy from 2-dimensional conventional radiotherapy, 3-dimensional conformal treatment, and intensity-modulated radiotherapy, respectively. The dose received by all other pelvic nodal regions was low and not clinically relevant.
CONCLUSION: The incidental dose received by obturator regions is significant especially with 2-dimensional conventional radiotherapy and 3-dimensional conformal treatment techniques as used in the trials studying elective pelvic nodal irradiation. However, with intensity-modulated radiotherapy, this dose is lower, making elective pelvic irradiation more relevant. Advances in Knowledge: This study highlights that incidental dose received by obturator regions is significant especially with 2-dimensional conventional radiotherapy and 3-dimensional conformal treatment techniques.

Entities:  

Keywords:  incidental dose; pelvic nodes; prostate cancer

Mesh:

Year:  2016        PMID: 27492806      PMCID: PMC5616032          DOI: 10.1177/1533034616661447

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  24 in total

1.  Effect of whole pelvic radiotherapy for patients with locally advanced prostate cancer treated with radiotherapy and long-term androgen deprivation therapy.

Authors:  Giovanna Mantini; Luca Tagliaferri; Gian Carlo Mattiucci; Mario Balducci; Vincenzo Frascino; Nicola Dinapoli; Cinzia Di Gesù; Edy Ippolito; Alessio G Morganti; Numa Cellini
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-01-27       Impact factor: 7.038

2.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer.

Authors:  Deborah A Kuban; Susan L Tucker; Lei Dong; George Starkschall; Eugene H Huang; M Rex Cheung; Andrew K Lee; Alan Pollack
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-08-31       Impact factor: 7.038

3.  A consensus-based guideline defining the clinical target volume for pelvic lymph nodes in external beam radiotherapy for uterine cervical cancer.

Authors:  Takafumi Toita; Tatsuya Ohno; Yuko Kaneyasu; Takashi Uno; Ryouichi Yoshimura; Takeshi Kodaira; Kazuhisa Furutani; Goro Kasuya; Satoshi Ishikura; Toshiharu Kamura; Masahiro Hiraoka
Journal:  Jpn J Clin Oncol       Date:  2010-02-04       Impact factor: 3.019

4.  Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06.

Authors:  S O Asbell; J M Krall; M V Pilepich; H Baerwald; W T Sause; G E Hanks; C A Perez
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-12       Impact factor: 7.038

5.  Whole-pelvis, "mini-pelvis," or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial.

Authors:  Mack Roach; Michelle DeSilvio; Richard Valicenti; David Grignon; Sucha O Asbell; Colleen Lawton; Charles R Thomas; William U Shipley
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-11-01       Impact factor: 7.038

6.  Acute toxicity in pelvic radiotherapy; a randomised trial of conformal versus conventional treatment.

Authors:  D M Tait; A E Nahum; L C Meyer; M Law; D P Dearnaley; A Horwich; W P Mayles; J R Yarnold
Journal:  Radiother Oncol       Date:  1997-02       Impact factor: 6.280

7.  Elective irradiation of subclinical disease in cancers of the head and neck.

Authors:  G H Fletcher
Journal:  Cancer       Date:  1972-06       Impact factor: 6.860

8.  Nonrandomized evaluation of pelvic lymph node irradiation in localized carcinoma of the prostate.

Authors:  C A Perez; J Michalski; K C Brown; M A Lockett
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-10-01       Impact factor: 7.038

9.  Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413.

Authors:  M Roach; M DeSilvio; C Lawton; V Uhl; M Machtay; M J Seider; M Rotman; C Jones; S O Asbell; R K Valicenti; S Han; C R Thomas; W S Shipley
Journal:  J Clin Oncol       Date:  2003-05-15       Impact factor: 44.544

10.  RTOG GU Radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer.

Authors:  Colleen A F Lawton; Jeff Michalski; Issam El-Naqa; Mark K Buyyounouski; W Robert Lee; Cynthia Menard; Elizabeth O'Meara; Seth A Rosenthal; Mark Ritter; Michael Seider
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-22       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.